These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 30762820)
1. Multifocal Small Bowel Carcinoid: Evaluation by 68Ga-DOTATATE PET. Clark M; Nathan M; Broski SM Clin Nucl Med; 2019 Apr; 44(4):e308-e310. PubMed ID: 30762820 [TBL] [Abstract][Full Text] [Related]
2. Incidental Finding of Cerebellar Medulloblastoma on 68Ga-DOTATATE PET/CT in a Patient With Appendiceal Carcinoid. Chan M; Hsiao E Clin Nucl Med; 2016 Nov; 41(11):886-887. PubMed ID: 27607158 [TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. Deppen SA; Liu E; Blume JD; Clanton J; Shi C; Jones-Jackson LB; Lakhani V; Baum RP; Berlin J; Smith GT; Graham M; Sandler MP; Delbeke D; Walker RC J Nucl Med; 2016 May; 57(5):708-14. PubMed ID: 26769865 [TBL] [Abstract][Full Text] [Related]
4. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. Sadowski SM; Neychev V; Millo C; Shih J; Nilubol N; Herscovitch P; Pacak K; Marx SJ; Kebebew E J Clin Oncol; 2016 Feb; 34(6):588-96. PubMed ID: 26712231 [TBL] [Abstract][Full Text] [Related]
5. Distinct Imaging Characteristics of Different Metastases From Primary Prostate Adenocarcinoma and Rectal Carcinoid Tumor on 18F-Fluciclovine and 68Ga-DOTATATE PET/CT. Bosserman AJ; Dai D; Lu Y Clin Nucl Med; 2019 Jan; 44(1):83-84. PubMed ID: 30371597 [TBL] [Abstract][Full Text] [Related]
7. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics. Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215 [TBL] [Abstract][Full Text] [Related]
8. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077 [TBL] [Abstract][Full Text] [Related]
9. Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT Upon Clinical Management. Kunikowska J; Lewington V; Krolicki L Clin Nucl Med; 2017 Dec; 42(12):905-911. PubMed ID: 29076910 [TBL] [Abstract][Full Text] [Related]
10. Osteoporosis Circumscripta on 68Ga-DOTATATE PET CT. Gandy N; Ordidge KL; Arshad M; Win Z Clin Nucl Med; 2019 Jun; 44(6):e404-e405. PubMed ID: 30985430 [TBL] [Abstract][Full Text] [Related]
11. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. Srirajaskanthan R; Kayani I; Quigley AM; Soh J; Caplin ME; Bomanji J J Nucl Med; 2010 Jun; 51(6):875-82. PubMed ID: 20484441 [TBL] [Abstract][Full Text] [Related]
12. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors? Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243 [TBL] [Abstract][Full Text] [Related]
13. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial. Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627 [TBL] [Abstract][Full Text] [Related]
14. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with Sampathirao N; Basu S J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019 [TBL] [Abstract][Full Text] [Related]
15. Long-Acting Somatostatin Analog Therapy Differentially Alters Ayati N; Lee ST; Zakavi R; Pathmaraj K; Al-Qatawna L; Poon A; Scott AM J Nucl Med; 2018 Feb; 59(2):223-227. PubMed ID: 28729431 [TBL] [Abstract][Full Text] [Related]
16. Comparison of (18F)FDG PET/CT and (68Ga)DOTATATE PET/CT imaging methods in terms of detection of histological subtype and related SUVmax values in patients with pulmonary carcinoid tumors. Komek H; Can C; Urakçi Z; Kepenek F Nucl Med Commun; 2019 May; 40(5):517-524. PubMed ID: 30694875 [TBL] [Abstract][Full Text] [Related]
17. Sensitivity Comparison of Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855 [TBL] [Abstract][Full Text] [Related]
18. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Ambrosini V; Castellucci P; Rubello D; Nanni C; Musto A; Allegri V; Montini GC; Mattioli S; Grassetto G; Al-Nahhas A; Franchi R; Fanti S Nucl Med Commun; 2009 Apr; 30(4):281-6. PubMed ID: 19247211 [TBL] [Abstract][Full Text] [Related]